<?xml version="1.0" encoding="UTF-8"?>
<p id="par0045">On 
 <bold>9th March,</bold> the second 
 <italic>in vitro</italic> clinical trial of chloroquine was published, this time comparing this drug with another from the same group, hydroxychloroquine, which differs in its molecular structure by incorporating a hydroxyl group, which gives it a series of specific properties, such as a greater immunomodulatory effect, possibly related to its action on toll-like receptors and the decrease in the production of IL-6, the role of which becomes important in the genesis of the macrophage activation syndrome
 <xref rid="bib0135" ref-type="bibr">
  <sup>4</sup>
 </xref> in these patients; as well as a better safety profile that allows higher doses to be used, and fewer interactions,
 <xref rid="bib0135" ref-type="bibr">4</xref>, 
 <xref rid="bib0170" ref-type="bibr">11</xref>, 
 <xref rid="bib0175" ref-type="bibr">12</xref> which make it especially attractive in older patients with comorbidities, often exposed to polypharmacy, who are most seriously affected by the virus.
</p>
